Table 3.

Actionable mutations. Tumour fractions and percentage of mutations are presented in this table with an example of agent and the phase of development that may be used

Gene	Tumour fraction	n	% patients	Example	Phase (cancer)
KRAS	32.3%	98	21.17%	MEK inhibitor	Phase III
NRAS	33.6%	90	19.44%	MEK inhibitor	Phase III
BRAF	25.2%	31	6.70%	Vemurafenib	Phase III
CCND1	41.7%	10	2.16%	Pablociclib	Phase I
FGFR3	37.1%	10	2.16%	Masitinib	Phase II
MLL	29.1%	8	1.73%	EPZ-5676	Phase I
ROS1	41.3%	8	1.73%	Foretinib	Phase II
RET	33.4%	6	1.30%	Cabozantinib	Phase II
ERBB4	42.3%	5	1.08%	Lapatinib	Phase II
FLT3	44.0%	5	1.08%	Sunitinib	Phase III
ERBB2	11.9%	3	0.65%	Herceptin	Phase III
FGFR2	66.7%	3	0.65%	Masitinib	Phase II
KIT	40.9%	3	0.65%	Ponatinib	Phase III
MAP2K1	14.9%	3	0.65%	MEK inh	Phase III
ABL1	53.3%	2	0.43%	Gleevec	Phase III
BRCA2	52.2%	2	0.43%	PPARP inhibitor (BMN673)	Phase I
DNMT3A	39.2%	2	0.43%	5-azacytidin	Phase III
EGFR	21.7%	2	0.43%	Erlotinib	Phase III
EPHB2	37.8%	2	0.43%	Herceptin	Phase III
PDGFRA	17.4%	2	0.43%	pazopanib	Phase I
BRCA1	6.4%	1	0.22%	PPARP inhibitor (BMN673)	Phase I
DDR2	58.3%	1	0.22%	Dasatinib	Phase III
FGFR4	28.6%	1	0.22%	Masitinib	Phase II
HIF1A	13.5%	1	0.22%	PX-478	Phase I
IDH2	17.9%	1	0.22%	AG-221	Phase I
KIF5B	5.9%	1	0.22%	Cabozantinib	Phase II
MET	39.8%	1	0.22%	MSC2156119J	Phase I
MPL	51.9%	1	0.22%	Eltrombopag	Phase III
PIK3CA	45.1%	1	0.22%	GDC-0941	Phase I
RARA	10.2%	1	0.22%	ATRA	Phase III